Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 15, Issue 6, Pages 579-602Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.15.6.579
Keywords
albaconazole; aspergillosis; Aspergillus spp.; Candida spp.; candidaemia; candidiasis; coccidioidomycosis; cryptococcal meningitis; fusariosis; histoplasmosis; posaconazole; ravuconazole; scedosporiasis; UK-109; 496; UR-9825; voriconazole; zygomycosis
Categories
Ask authors/readers for more resources
New triazole antifungals (voriconazole, posaconazole, ravuconazole and albaconazole) have been developed to meet the increasing need for new antifungals, and address the rising incidence of invasive fungal infections and the emergence of fungal resistance. This report describes the spectrum of activity of the newer-generation triazoles based on data from in vitro, animal and clinical studies. The authors discuss the use of these agents in combination with other antifungals, the extent of cross-resistance, their toxicity profile and pharmacokinetic proper-ties. A total of two agents are currently available: voriconazole (which is becoming a primary treatment for the management of invasive aspergillosis) and posaconazole (which demonstrates a broad antifungal spectrum). A further two agents, albaconazole and ravuconazole, are undergoing early clinical evaluation and their future is uncertain. For all newer triazoles, concerns about emerging drug-resistant fungi and the incidence and management of breakthrough infections will dictate their role in antifungal prophylaxis and treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available